ClinicalTrials.gg
CompletedNCT04066777Post-TASHUpdated Nov 18, 2023

The Effect of TASH in Patients With HOCM

An interventional study of alcohol septal ablation in Hypertrophic Obstructive Cardiomyopathy, sponsored by Steen Hvitfeldt Poulsen. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Steen Hvitfeldt Poulsen · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Cardiomyopathy, Hypertrophic with a site in Denmark — 2 open to participants now, 3 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · Denmark.

Enrollment
12th of 12
24 · median 213
Started
2019
the only one that year
No phase
2 of 12
none open now
Registered
6th of 12
by date
Lead sponsor
2 of 12
Steen Hvitfeldt Poulsen

Among the 12 studies in Cardiomyopathy, Hypertrophic with a site in Denmark, this one is the 12th largest by enrollment, is the only one that started in 2019, is one of 2 with no phase, and was the 6th registered.

Cardiomyopathy, Hypertrophic

365 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 118 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

2 of the 12 studies in Cardiomyopathy, Hypertrophic with a site in Denmark are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 82 Cardiomyopathy, Hypertrophic studies recruiting now, 56 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Cardiomyopathy, Hypertrophic with a site in Denmark, or all of them as a file.
02

Study summary

To examine patients with hypertrophic obstructive cardiomyopathy (HOCM) before and after septal alcohol ablation, to investigate the effect of the treatment in regards to changes in myocardial function, perfusion, invasive hemodynamics and exercise tolerance.

Read the detailed description

Patients with HOCM who develop symptoms of heart failure are treated initially with non-vasodilating ß-blockers or verapamil to decrease myocardial contractility and heart rate. A substantial part of patients remain symptomatic despite medical treatment. In these patients interventional or surgical treatments (septal reduction therapies (SRT)) to reduce left ventricular outflow tract obstruction (LVOTO) is considered in the presence of moderate to-severe symptoms (New York Heart Association - functional class (NYHA) III-IV) and/or recurrent exertional syncope and an LVOTO gradient ≥50 mm Hg. In some centers, invasive therapy is also considered in patients with mild symptoms (NYHA Class II) who have a resting or maximum provoked gradient of ≥50 mm Hg (with exercise or Valsalva's maneuver) and moderate-to-severe mitral valve regurgitation. Advanced treatment options are alcohol septal ablation (ASA) or surgical myectomy often combined with mitral valve reconstructive surgery. These treatments have similar outcomes in terms of gradient reduction, symptom improvement and exercise capacity

No previous trials have examined the effect of ASA in HOCM with respect to changes in central hemodynamics and myocardial performance during exercise.

24 HOCM patients will be examined prior to ASA, and approximately six-nine months after ASA.

The examination set-up consists of simultaneous 1) transthoracic echocardiography (TTE), 2) right heart catheterization (RHC) and 3) cardiopulmonary exercise test (CPX).

03

Conditions studied

  • Hypertrophic Obstructive Cardiomyopathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Left ventricular wall thickness ≥ 15 mm in one or more myocardial segments that is not explained by loading conditions
  • LVOT gradients ≥ 30 mmHg at rest and/or ≥ 50 mmHg at Valsalva's maneuver or exercise
  • ≥ III

Exclusion criteria

Exclusion Criteria:

  • \< 18 years
  • Fertile women who do not use anti-
  • Pregnancy
  • Patients are allowed to have a pacemaker (eg. an implantable cardioverter defibrillator (ICD)) but cannot be pace-dependent
  • Amiodarone treatment
  • Persistent or permanent atrial fibrillation/flutter
  • Previous SRT
  • Alcohol or drug abuse
  • Significant co-morbidity (judged by the investigator)
  • Patients who cannot give valid consent (e.g. mental illness or dementia) or who do not understand Danish.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Other
    Hypertrophic obstructive cardiomyopathy

    injection of 1-4 mL of 96% ethanol into a septal perforator of the left anterior coronary artery to produce a myocardial infarction

    Procedure: alcohol septal ablation

Interventions

  • Procedurealcohol septal ablation

    injection of 1-4 mL of 96% ethanol into a septal perforator of the left anterior coronary artery to produce a myocardial infarction

06

What researchers measure

Primary outcomes

  1. Pulmonary capillary wedge pressure (PCWP) during exercise

    Change in PCWP at 75 watt (or maximum exercise, if this is \< 75 W)

    Time frame: Changes will be evaluated after an expected average of 6-9 months after treatment

Secondary outcomes

  1. Pulmonary capillary wedge pressure (PCWP) at rest

    Changes in PCWP at rest

    Time frame: Changes will be evaluated after an expected average of 6-9 months after treatment

  2. Peak oxygen uptake (VO2-max)

    Changes in maximal oxygen consumption (L/min) measured during cardiopulmonary exercise test

    Time frame: Changes will be evaluated after an expected average of 6-9 months after treatment

  3. Work capacity

    work capacity measured in watt during a cardiopulmonary exercise test

    Time frame: Changes will be evaluated after an expected average of 6-9 months after treatment

  4. LVOT gradient during maximum exercise

    Changes of the LVOT gradient during maximum exercise, measured in mmHg during 2D echocardiography

    Time frame: Changes will be evaluated after an expected average of 6-9 months after treatment

  5. Coronary flow reserve

    Changes in the ratio of maximum coronary blood flow (induced by infusion of adenosin) to resting coronary blood flow, estimated by 2D doppler echocardiography

    Time frame: Changes will be evaluated after an expected average of 6-9 months after treatment

  6. Changes in biomarkers

    Changes in N-terminal pro-brain natriuretic peptide (NT-proBNP) ng/l and troponin T ng/l

    Time frame: Changes will be evaluated after an expected average of 6-9 months after treatment

  7. Change in GLS (%) at peak exercise

    Change in global longitudinal strain (GLS) in % at peak exercise

    Time frame: Changes will be evaluated after an expected average of 6-9 months after treatment

  8. Changes of symptoms and quality of life estimated by KCCQ

    Changes of symptoms and quality of life with Kansas City Cardiomyopathy Questionnaire (KCCQ) assessed by clinical evaluation

    Time frame: Changes will be evaluated after an expected average of 6-9 months after treatment

07

Study locations

1 site
  • Aarhus University Hospital, Department of Cardiology
    Aarhus N, Danmark 8200, Denmark
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Oct 2023, 52 months.

Of 47 non-industry interventional studies with no phase under Cardiomyopathy, Hypertrophic, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 52 months is above that.

Counting every sponsor, half of 52 studies reached it within 52 months; a quarter within 26 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2019
First posted
Aug 26, 2019
StartActual
May 29, 2019
Primary completionActual
Oct 1, 2023
CompletionActual
Oct 1, 2023
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04066777
Lead sponsor
Steen Hvitfeldt Poulsen
Responsible party
Steen Hvitfeldt Poulsen (professor, Aarhus University Hospital Skejby) — Sponsor-investigator
First posted
Aug 26, 2019
Start date
May 29, 2019
Primary completion
Oct 1, 2023
Completion
Oct 1, 2023
Last update
Nov 18, 2023

Study contacts

Steen Hvitfeldt Poulsen, DMSc
principal investigator · Aarhus University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion